MBX Biosciences, Inc. MBX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about MBX Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MBX Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments?
- MBX Biosciences, Inc. (MBX) reported accretion (amortization) of discounts and premiums, investments of $579K in Q1 2026.
- How has MBX Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- MBX Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 56.9% year-over-year, from $1.34M to $579K.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This reflects the non-cash adjustment to the carrying value of investment securities held by the company, accounting for the amortization of premiums or accretion of discounts over the life of the instrument. It reconciles the difference between the purchase price and the face value of debt securities. This adjustment is necessary to align reported interest income with the effective interest method.